Sistema de Salut de Catalunya
[Ariza M] Unitat de Psicologia Mèdica, Departament de Medicina, Universitat de Barcelona, Barcelona, Spain. Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain. Grup de Recerca en Cervell, Cognició I Conducta, Consorci Sanitari de Terrassa (CST), Terrassa, Spain. [Cano N] Unitat de Psicologia Mèdica, Departament de Medicina, Universitat de Barcelona, Barcelona, Spain. Grup de Recerca en Cervell, Cognició I Conducta, Consorci Sanitari de Terrassa (CST), Terrassa, Spain. Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Spain. [Segura B] Unitat de Psicologia Mèdica, Departament de Medicina, Universitat de Barcelona, Barcelona, Spain. Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain. Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain. Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain. [Adan A] Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain. Departament de Psicologia Clínica I Psicobiologia, Universitat de Barcelona, Barcelona, Spain. [Bargalló M] Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain. Diagnostic Imaging Centre, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Barcelona, Spain. [Caldú X] Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain. Departament de Psicologia Clínica I Psicobiologia, Universitat de Barcelona, Barcelona, Spain. Institut de Recerca de Sant Joan de Déu (IRSJD), Esplugues de Llobregat, Spain. [Garolera M] Grup de Recerca en Cervell, Cognició I Conducta, Consorci Sanitari de Terrassa (CST), Terrassa, Spain. Neuropsychology Unit, Consorci Sanitari de Terrassa (CST), Terrassa, Spain
Consorci Sanitari de Terrassa
2024-03-25T14:16:55Z
2024-03-25T14:16:55Z
2023-05
COVID-19; Neuropsychological test; Symptom assessment
COVID-19; Prueba neuropsicológica; Evaluación de síntomas
COVID-19; Prova neuropsicològica; Avaluació de símptomes
Patients with post-coronavirus disease 2019 (COVID-19) conditions typically experience cognitive problems. Some studies have linked COVID-19 severity with long-term cognitive damage, while others did not observe such associations. This discrepancy can be attributed to methodological and sample variations. We aimed to clarify the relationship between COVID-19 severity and long-term cognitive outcomes and determine whether the initial symptomatology can predict long-term cognitive problems. Cognitive evaluations were performed on 109 healthy controls and 319 post-COVID individuals categorized into three groups according to the WHO clinical progression scale: severe-critical (n = 77), moderate-hospitalized (n = 73), and outpatients (n = 169). Principal component analysis was used to identify factors associated with symptoms in the acute-phase and cognitive domains. Analyses of variance and regression linear models were used to study intergroup differences and the relationship between initial symptomatology and long-term cognitive problems. The severe-critical group performed significantly worse than the control group in general cognition (Montreal Cognitive Assessment), executive function (Digit symbol, Trail Making Test B, phonetic fluency), and social cognition (Reading the Mind in the Eyes test). Five components of symptoms emerged from the principal component analysis: the "Neurologic/Pain/Dermatologic" "Digestive/Headache", "Respiratory/Fever/Fatigue/Psychiatric" and "Smell/ Taste" components were predictors of Montreal Cognitive Assessment scores; the "Neurologic/Pain/Dermatologic" component predicted attention and working memory; the "Neurologic/Pain/Dermatologic" and "Respiratory/Fever/Fatigue/Psychiatric" components predicted verbal memory, and the "Respiratory/Fever/Fatigue/Psychiatric," "Neurologic/Pain/Dermatologic," and "Digestive/Headache" components predicted executive function. Patients with severe COVID-19 exhibited persistent deficits in executive function. Several initial symptoms were predictors of long-term sequelae, indicating the role of systemic inflammation and neuroinflammation in the acute-phase symptoms of COVID-19." Study Registration: www.ClinicalTrials.gov , identifier NCT05307549 and NCT05307575.
Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature
Article
Published version
English
COVID-19 (Malaltia); Tests neuropsicològics; Trastorns de la cognició; DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections::Severe Acute Respiratory Syndrome; Other subheadings::Other subheadings::Other subheadings::/complications; PSYCHIATRY AND PSYCHOLOGY::Mental Disorders::Neurocognitive Disorders::Cognition Disorders; PSYCHIATRY AND PSYCHOLOGY::Behavioral Disciplines and Activities::Psychological Tests::Neuropsychological Tests; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus::síndrome respiratorio agudo grave; Otros calificadores::Otros calificadores::Otros calificadores::/complicaciones; PSIQUIATRÍA Y PSICOLOGÍA::trastornos mentales::trastornos neurocognitivos::trastornos cognitivos; PSIQUIATRÍA Y PSICOLOGÍA::disciplinas y actividades conductuales::pruebas psicológicas::pruebas neuropsicológicas
Springer
Journal of Neurology;270(5)
http://doi.org/10.1007/s00415-023-11587-4
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
